Last reviewed · How we verify
NCT07398001
Discontinuation of Antiplatelet Therapy After Drug-Coated Balloon Treatment
NA trial testing Stop Antiplatelet in Percutaneous Coronary Intervention in 1,042 participants. Not yet recruiting.
11 February 2028
Quick facts
| Lead sponsor | Ulsan University Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 1,042 |
| Start date | 12 February 2026 |
| Primary completion | 11 February 2028 |
| Estimated completion | 31 July 2030 |
| Sites | 7 locations across South Korea |
Drugs / interventions tested
- Stop Antiplatelet — full drug profile →
- Continue Antiplatelet — full drug profile →
Conditions studied
- Percutaneous Coronary Intervention — all drugs for Percutaneous Coronary Intervention →
- Antiplatelet Therapy — all drugs for Antiplatelet Therapy →
- Drug-coated Balloon — all drugs for Drug-coated Balloon →
Sponsor
Ulsan University Hospital
Who can join
19 and older, any sex, with Percutaneous Coronary Intervention or Antiplatelet Therapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to evaluate the benefits and risks of discontinuing antiplatelet therapy on clinical outcomes in patients who previously underwent coronary intervention using a drug-coated balloon. The main questions it aims to answer are: Does stopping antiplatelet therapy after 12 months affect the risk of net adverse clinical events? Does stopping antiplatelet therapy reduce the risk of bleeding compared with continuing treatment? Researchers will compare patients who discontinue antiplatelet therapy with patients who continue antiplatelet therapy to determine the impact on clinical outcomes during follow-up. Participants will: Be randomly assigned to either discontinue or continue antiplatelet therapy Receive routine clinical follow-up through clinic visits or telephone contacts Be monitored for cardiovascular events and bleeding outcomes over time
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07398001
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Percutaneous Coronary Intervention
Currently open trials in the same condition.
- NCT07231939 — Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI · recruiting
- NCT07378163 — Study on the Preferences for PCI Implantation Devices Among Doctors and Patients · recruiting
- NCT07378137 — Comparing the Components of Composite Endpoints for Healthcare Providers and Patients · recruiting
- NCT06878729 — Antegrade Dissection and Re-entry Versus Retrograde Strategy in CTO PCI · NA · recruiting
- NCT07446023 — IVUS-FFR Accuracy for Coronary Stenosis · NA · recruiting
Other Ulsan University Hospital trials
Trials by the same sponsor.
- NCT07057648 — Shape-Sensing Robotic-Assisted Bronchoscopy for Diagnosis of Peripheral Pulmonary Nodules in Korea · recruiting
- NCT03270852 — Enhanced Reality for Hemiparetic Arm in the Stroke Patients · NA · unknown
- NCT03787524 — Prediction of Functional Health Status and Aspiration Using Multiple Dysphagia Scales Over 6 Months After Acute Stroke · unknown
- NCT03789409 — Intermittent Fasting Following Acute Ischemic Stroke · NA · unknown
- NCT03779815 — Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07398001 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ulsan University Hospital
- Last refreshed: 9 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07398001.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing